Marksans Pharma Overview

  • Year Founded
  • 1992

Year Founded

  • Status
  • Public

  • Employees
  • 2,235

Employees

  • Stock Symbol
  • MARKSANS

Stock Symbol

  • Investments
  • 9

  • Share Price
  • $3.20
  • (As of Thursday Closing)

Marksans Pharma General Information

Description

Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.

Contact Information

Formerly Known As
Glenmark Laboratories
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 11th Floor, Grandeur, Opposite Gundecha Symphony
  • Off Veera Desai Extension Road, Oshiwara, Andheri West
  • Mumbai, Maharashtra 400053
  • India
+91 022
Primary Industry
Drug Discovery
Stock Exchange
NSE
Corporate Office
  • 11th Floor, Grandeur, Opposite Gundecha Symphony
  • Off Veera Desai Extension Road, Oshiwara, Andheri West
  • Mumbai, Maharashtra 400053
  • India
+91 022

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Marksans Pharma Stock Performance

As of 19-Nov-2026, Marksans Pharma’s stock price is $3.20. Its current market cap is $1.45B with 453M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.20 $3.15 $1.64 - $3.70 $1.45B 453M 1.88M $0.13

Marksans Pharma Financials Summary

As of 30-Sep-2026, Marksans Pharma has a trailing 12-month revenue of $366M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 1,456,422 717,014 1,122,814 749,230
Revenue 365,783 332,902 309,192 262,629
EBITDA 95,165 74,197 67,270 57,403
Net Income 60,377 47,293 45,008 37,893
Total Assets 453,885 409,199 378,730 321,482
Total Debt 48,370 36,393 37,633 29,266
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Marksans Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Marksans Pharma‘s full profile, request access.

Request a free trial

Marksans Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of
Drug Discovery
Mumbai, India
2,235 As of 2026

Mumbai, India
 

Basel, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Marksans Pharma Competitors (15)

One of Marksans Pharma’s 15 competitors is Evonile Pharma, a Private Equity-Backed company based in Mumbai, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Evonile Pharma Private Equity-Backed Mumbai, India
Novartis Corporation Basel, Switzerland
Torrent Pharmaceuticals Corporation Ahmedabad, India
Aurobindo Pharma Corporation Hyderabad, India
Biocon Formerly PE-Backed Bengaluru, India
You’re viewing 5 of 15 competitors. Get the full list »

Marksans Pharma Patents

Marksans Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220079894-A1 Stable pharmaceutical compositions Inactive 11-Sep-2020
WO-2008001389-A2 Female contraceptive for transcervical delivery and its' preparation Inactive 27-Jun-2006
WO-2008001389-A3 Female contraceptive for transcervical delivery and its' preparation Inactive 27-Jun-2006 A61K31/194

Marksans Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Marksans Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Marksans Pharma‘s full profile, request access.

Request a free trial

Marksans Pharma Investments & Acquisitions (9)

Marksans Pharma’s most recent deal was a Merger/Acquisition with ABCnow for . The deal was made on 20-Jul-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ABCnow 20-Jul-2026 Merger/Acquisition Distributors (Healthcare)
QliniQ 16-Jun-2026 Merger/Acquisition Medical Supplies
Teva pharm India (manufacturing Unit) 19-Apr-2023 Corporate Asset Purchase Buildings and Property
Tevapharm (Pharmaceutical Formulations Business) 18-Apr-2023 Merger/Acquisition Pharmaceuticals
Access Healthcare (Media and Information Services (B2B)) 06-Jun-2022 Merger/Acquisition Media and Information Services (B2B)
You’re viewing 5 of 9 investments and acquisitions. Get the full list »

Marksans Pharma ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

31.21 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Marksans Pharma’s complete esg history, request access »

Marksans Pharma Exits (1)

Marksans Pharma’s most recent exit was on 18-Jan-2008 from Hale Group. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Hale Group 18-Jan-2008 Completed
To view Marksans Pharma’s complete exits history, request access »

Marksans Pharma Affiliates

Subsidiaries (5)

Name Industry Location Year Founded
QliniQ Oldenzaal, Netherlands 2007
Relonchem Widnes, United Kingdom 2002
Time-Cap Labs Farmingdale, NY 1979
Bell's Healthcare Widnes, United Kingdom 1939
Access Healthcare (Media and Information Services (B2B)) Dubai, United Arab Emirates

Marksans Pharma FAQs

  • When was Marksans Pharma founded?

    Marksans Pharma was founded in 1992.

  • Where is Marksans Pharma headquartered?

    Marksans Pharma is headquartered in Mumbai, India.

  • What is the size of Marksans Pharma?

    Marksans Pharma has 2,235 total employees.

  • What industry is Marksans Pharma in?

    Marksans Pharma’s primary industry is Drug Discovery.

  • Is Marksans Pharma a private or public company?

    Marksans Pharma is a Public company.

  • What is Marksans Pharma’s stock symbol?

    The ticker symbol for Marksans Pharma is MARKSANS.

  • What is the current stock price of Marksans Pharma?

    As of 19-Nov-2026 the stock price of Marksans Pharma is $3.20.

  • What is the current market cap of Marksans Pharma?

    The current market capitalization of Marksans Pharma is $1.45B.

  • What is Marksans Pharma’s current revenue?

    The trailing twelve month revenue for Marksans Pharma is $366M.

  • Who are Marksans Pharma’s competitors?

    Evonile Pharma, Novartis, Torrent Pharmaceuticals, Aurobindo Pharma, and Biocon are some of the 15 competitors of Marksans Pharma.

  • What is Marksans Pharma’s annual earnings per share (EPS)?

    Marksans Pharma’s EPS for 12 months was $0.13.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process